Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (451)	12/27/1997 4:19:00 PM
From: Bharat H. Barai	Read Replies (2) \| Respond to of 834

Dear Bill, I am perplexed at your statement that HIT trial did not show statistically significant difference. I can understand you expressing your opinions. How can you change the facts? I would urge you to check your information and get facts on HIT trials. It is my recollection that the p value was less than .004. That is very highly statistically significant difference! I have personally attended some meetings where Novastan data was presented. The data for HIT looked very impressive! I respect your right to give your opinion about past performance of TXB. I am sure Smith Kline Beecham did some homework before giving 11 Million Dollars to TXB and tying them in partnership with TXB. B.H. Barai MD Hematologist